Cost-effectiveness of natalizumab versus fingolimod for the treatment of relapsing multiple sclerosis

References

• National Multiple Sclerosis Society. Who gets MS? Available at: http://www.nationalmssociety.org/index.aspx [Last accessed 10 December 2010]
   Google Scholar
• Wingerchuck DM, Weinshenker BG. Multiple sclerosis: epidemiology, genetics, classification, natural history, and clinical outcome measures. Adv Mult Scler 2000;10:611-23
   Google Scholar
• Ryan M, Piascik P. Providing pharmaceutical care to the multiple sclerosis patient. J Am Pharm Assoc 2002;42:753-67
   Google Scholar
• Whetten-Goldstein K, Sloan FA, Goldstein LB, et al. A comprehensive assessment of the cost of multiple sclerosis in the United States. Mult Scler 1998;4:419-25
   PubMed Web of Science ®Google Scholar
• Prescott JD, Factor S, Pill M, et al. Descriptive analysis of the direct medical costs of multiple sclerosis in 2004 using administrative claims in a large nationwide database. J Manag Care Pharm 2007;13:44-52
   PubMed Web of Science ®Google Scholar
• Asche CV, Singer ME, Jhaveri M, et al. All-cause health care utilization and costs associated with newly diagnosed multiple sclerosis in the United States. J Manag Care Pharm 2010;16:703-12
   PubMed Web of Science ®Google Scholar
• Pope GC, Urato CJ, Kulas ED, et al. Prevalence, expenditures, utilization, and payment for persons with MS in insured populations. Neurology 2002;58:37-43
   PubMed Web of Science ®Google Scholar
• Kunze AM, Gunderson BW, Gleason PP, et al. Utilization, cost trends, and member cost-share for self-injectable multiple sclerosis drugs – pharmacy and medical benefit spending from 2004 through 2007. J Manag Care Pharm 2007;13:799-806
   PubMed Web of Science ®Google Scholar
• Schafer JA, Gunderson BW, Gleason PP. Price increases and new drugs drive increased expenditures for multiple sclerosis. J Manag Care Pharm 2010;16:713-17
   PubMed Web of Science ®Google Scholar
• O’Brien JA, Ward AJ, Patrick AR, et al. Cost of managing an episode of relapse in multiple sclerosis in the United States. BMC Health Serv Res 2003;3:17-28
   PubMed Web of Science ®Google Scholar
• US Bureau of Labor Statistics. Consumer Price Index – July 2010. Washington, DC: US Bureau of Labor Statistics
   Google Scholar
• Kieseier BC, Stüve O. A critical appraisal of treatment decisions in multiple sclerosis – old versus new. Nat Rev Neurol 2011;7:255-62. [Epub 2011 Apr 5]
   Google Scholar
• Gilenya (fingolimod) [package insert]. East Hanover, NJ: Novartis, 2010
   Google Scholar
• Gilenya Risk Evaluation and Mitigation Strategy (REMS). Novartis Pharmaceuticals Corporation. Approved REMS dated September 21, 2010
   Google Scholar
• Cohen JA, Barkhof F, Comi G, et al; for the TRANSFORMS study group. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. NEJM 2010;362:402-15
   PubMed Web of Science ®Google Scholar
• Comi G, O’Conner P, Montalban X, et al. Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year results. Mult Scler 2010;16:197-207
   PubMed Web of Science ®Google Scholar
• Portaccio E. Evidence-based assessment of potential use of fingolimod in treatment of relapsing multiple sclerosis. Core Evidence 2010;6:13-21
   Google Scholar
• Goldberg LD, Edwards NC, Fincher C, et al. Comparing the cost-effectiveness of disease-modifying drugs for the first-line treatment of relapsing–remitting multiple sclerosis. J Manag Care Pharm 2009;15:543-55
   PubMed Web of Science ®Google Scholar
• Bell C, Graham J, Earnshaw S, et al. Cost-effectiveness of four immunomodulatory therapies for relapsing–remitting multiple sclerosis: a Markov model based on long-term clinical data. J Manag Care Pharm 2007;13:245-61
   PubMed Web of Science ®Google Scholar
• Gani R, Giovannoni G, Bates D, et al. Cost-effectiveness analyses of natalizumab (Tysabri) compared with other disease-modifying therapies for people with highly active relapsing–remitting multiple sclerosis in the UK. Pharmacoeconomics 2008;26:617-27
   PubMed Web of Science ®Google Scholar
• Chiao E, Meyer K. Cost effectiveness and budget impact of natalizumab in patients with relapsing multiple sclerosis. Curr Med Res Opin 2009;25:1445-54
   PubMed Web of Science ®Google Scholar
• Tysabri (natalizumab) [package insert]. Cambridge, MA, USA: Biogen Idec, Inc., 2010
   Google Scholar
• Avonex [package insert]. Cambridge, MA, USA: Biogen Idec, Inc., 2008
   Google Scholar
• Betaseron [package insert]. Montville, NJ, USA: Bayer HealthCare Pharmaceuticals Inc., 2010
   Google Scholar
• Copaxone [package insert]. Kansas City, MO, USA: Teva Neuroscience, Inc., 2009
   Google Scholar
• Extavia [package insert]. East Hanover, NJ, USA: Novartis Pharmaceuticals Corporation, 2009
   Google Scholar
• Rebif [package insert]. Rockland, MA, USA: Serono, Inc., 2009
   Google Scholar
• Joyce AT, Iacoviello JM, Nag S, et al. End-stage renal disease – associated managed care costs among patients with and without diabetes. Diabetes Care 2004;27:2829-35
   PubMed Web of Science ®Google Scholar
• Polman CH, O’Connor PW, Havrdova E, et al; AFFIRM Investigators. A randomized placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006;354:899-910
   PubMed Web of Science ®Google Scholar
• Kappos L, Radue W, O’Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010;362:387-401
   PubMed Web of Science ®Google Scholar
• Biogen Idec Med Info. PML incidence in patients receiving Tysabri. Available at: https://medinfo.biogenidec.com [registration required] [Last accessed 27 January 2011]
   Google Scholar
• Campbell DE, Lynn J, Louis TA, et al. Medicare program expenditures associated with hospice use. Ann Intern Med 2004;140:269-77
   PubMed Web of Science ®Google Scholar
• Centers for Medicare & Medicaid Services. Physician Fee Schedule, 2010 (210B file). Available at: http://www.cms.gov/pfslookup/02_PFSsearch.asp [Last accessed 28 February 2011]
   Google Scholar
• Kilgore PE, Kruszon-Moran D, Seward JF, et al. Varicella in Americans from NHANES III: implications for control through routine immunization. J Med Virol 2003;70(Suppl 1):S111-18
   PubMedGoogle Scholar
• Centers for Disease Control and Prevention. National diabetes fact sheet: general information and national estimates on diabetes in the United States, 2007. Atlanta, GA, USA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, 2008
   Google Scholar
• Multiple sclerosis – natalizumab: natalizumab for the treatment of adults with highly active relapsing–remitting multiple sclerosis. National Institute for Health and Clinical Excellence (NICE), August 2007. Available at: http://www.nice.org.uk/Guidance/TA127 [Last accessed 28 February 2011]
   Google Scholar
• Fox EJ. Emerging oral agents for multiple sclerosis. Am J Manag Care 2010;16:S219-S26
   PubMed Web of Science ®Google Scholar
• Lipsy R. Will the newer oral MS agents be welcomed by managed care organizations? Am J Manag Care 2010;16:S227-S33
   PubMedGoogle Scholar
• Treadway K, Cutter G, Salter A, et al. Factors that influence adherence with the disease-modifying therapy in MS. J Neurol 2009;256:568-76
   PubMedGoogle Scholar
• Rao SM. Neuropsychology of multiple sclerosis. Curr Opin Neurol 1995;8:216-20
   PubMed Web of Science ®Google Scholar
• Confavreux C, Vukusic S, Moreau T, et al. Relapses and progression of disability in multiple sclerosis. N Engl J Med 2000;343:1430-8
   PubMed Web of Science ®Google Scholar
• Young PJ, Lederer C, Eder K, et al. Sylvia Lawry Centre for Multiple Sclerosis Research. Relapses and subsequent worsening of disability in relapsing–remitting multiple sclerosis. Neurology 2006;67:804-8
   PubMedGoogle Scholar
• American Academy of Neurology Guidelines 2002. Available at: http://www.aan.com/go/practice/guidelines [Last accessed 28 February 2011]
   Google Scholar